Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNALGOS-DC vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydrocodeine is a semisynthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby providing analgesic and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia by reducing pain perception and increasing the efficacy of other analgesics.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Moderate to moderately severe pain,Relief of pain accompanied by inflammation or fever (off-label)
Mild to moderate pain,Fever
1-2 capsules orally every 4 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg. Maximum: 8 capsules per day.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Dihydrocodeine: 3.5-4.5 hours; aspirin: 15-20 minutes; caffeine: 3-6 hours. Context: Dihydrocodeine half-life supports q4-6h dosing; aspirin short half-life limits analgesia duration.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Dihydrocodeine is metabolized primarily via O-demethylation and N-demethylation in the liver, mediated by CYP2D6 and CYP3A4, to active metabolites including dihydromorphine. Aspirin is hydrolyzed to salicylic acid, which undergoes conjugation with glycine and glucuronic acid, and oxidative metabolism. Caffeine is metabolized by CYP1A2 to paraxanthine, theobromine, and theophylline.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: ~90% (dihydrocodeine, as metabolites, primarily glucuronides); biliary/fecal: ~10%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Dihydrocodeine: ~20-30% (albumin); aspirin: ~50-80% (albumin, saturable); caffeine: ~25-36% (albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Dihydrocodeine: 1.2-1.7 L/kg; clinical meaning: distributes extensively into tissues, including CNS.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: Dihydrocodeine ~70-80% (first-pass metabolism); aspirin: 40-50% (due to hydrolysis in gut wall/liver); caffeine: nearly 100%.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Avoid use if Cr Cl < 30 m L/min due to accumulation of dihydrocodeine and acetaminophen. For Cr Cl 30-60 m L/min, extend dosing interval to every 6 hours and monitor closely. For Cr Cl > 60 m L/min, no adjustment needed.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% and monitor for hepatotoxicity. In mild impairment (Child-Pugh A), no adjustment but caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not recommended for pediatric patients due to variable metabolism of dihydrocodeine and risk of respiratory depression. Specific weight-based dosing not established; alternative agents preferred.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at lowest effective dose (1 capsule every 6 hours). Monitor for CNS depression, falls, and constipation. Avoid in frail elderly due to increased sensitivity and risk of toxicity from acetaminophen accumulation.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE OF BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS FROM CONCOMITANT USE WITH ALCOHOL. See full prescribing information.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,CYP3A4 interaction (potent inhibitors or inducers),Concomitant use with benzodiazepines or other CNS depressants,Risk of bleeding (aspirin),Reye's syndrome (aspirin use in viral infections in children),Serotonin syndrome (with serotonergic drugs),Adrenal insufficiency,Hypotension, including orthostatic hypotension,Seizures,Increased intracranial pressure,Gastrointestinal adverse effects (aspirin),Renal impairment,Hepatic impairment
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to dihydrocodeine, aspirin, caffeine, or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Severe bleeding disorders (aspirin),Children and teenagers with viral infections (risk of Reye's syndrome),Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy,Severe hepatic impairment,Severe renal impairment
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol and grapefruit juice. High-fat meals may delay the absorption of dihydrocodeine, potentially reducing the peak effect. Maintain adequate hydration to prevent constipation. No other specific dietary restrictions.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: Association with neural tube defects and congenital heart defects with opioid use. Second/third trimesters: Risk of miscarriage, preterm birth, fetal growth restriction, and neonatal abstinence syndrome with chronic use. No specific data on dihydrocodeine combination; teratogenic risk considered low from oral contraceptives, but paracetamol/aspirin/caffeine components may contribute.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Dihydrocodeine and paracetamol are excreted into breast milk. Milk-to-plasma ratio (M/P) for dihydrocodeine is approximately 2.4; for paracetamol, M/P ~1.0 (but clinically negligible). Aspirin (as present in some formulations) is excreted with M/P 0.01–0.1; risk of Reye syndrome in infants. Caffeine M/P ~0.5–0.8. Use caution; benefit-risk evaluation required.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy generally increases clearance of paracetamol and dihydrocodeine; however, no specific dose adjustment recommendations. Use lowest effective dose for shortest duration. Consider avoiding aspirin component in third trimester due to premature ductus arteriosus closure risk. Caffeine dose not adjusted but limit intake.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
SYNALGOS-DC contains dihydrocodeine, a prodrug metabolized to dihydromorphine via CYP2D6. Co-administration with CYP2D6 inhibitors (e.g., paroxetine) or inducers may alter analgesia. Avoid in patients with severe respiratory depression, paralytic ileus, or history of opioid addiction. Monitor for serotonin syndrome if combined with serotonergic agents. Use with caution in elderly or debilitated patients due to increased fall risk.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Do not exceed the prescribed dose; risk of addiction and overdose increases with higher doses.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they may cause dangerous sedation or respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take with food if nausea occurs; avoid high-fat meals as they may delay absorption.,Store in a secure place; dispose of unused medication via take-back programs to prevent misuse.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNALGOS-DC vs ACEPHEN, answered by our medical review team.
SYNALGOS-DC is a Opioid Analgesic that works by Dihydrocodeine is a semisynthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby providing analgesic and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia by reducing pain perception and increasing the efficacy of other analgesics.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNALGOS-DC and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNALGOS-DC is: 1-2 capsules orally every 4 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg. Maximum: 8 capsules per day.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNALGOS-DC and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNALGOS-DC is classified as Category C. First trimester: Association with neural tube defects and congenital heart defects with opioid use. Second/third trimesters: Risk of miscarriage, preterm birth, fetal growth restri. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.